Davide Leone & Partners Investment Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,734	Closed	-$896K	–	135
2021 Q1	$896K	Buy	+9,734	New	+$821K	0.11%	92

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Davide Leone & Partners Investment Company's HZNP Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 9,734 shares — an estimated $896K sold.

Davide Leone & Partners Investment Company first reported a position in HZNP in Q1 2021 and held it in 1 quarter. The position peaked at $896K in Q1 2021. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

Davide Leone & Partners Investment Company reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
Davide Leone & Partners Investment Company sold 9,734 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $896K.
Davide Leone & Partners Investment Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 1 quarter.
Davide Leone & Partners Investment Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $896K in Q1 2021.
526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.